Answers are grounded in this paper and cite their sources.
Treatment with weekly rilonacept provided marked and lasting improvement in the clinical signs and symptoms of CAPS, and normalized the levels of SAA from those associated with risk of developing amyloidosis. Rilonacept exhibited a generally favorable safety and tolerability profile.
No takes yet. Share an insight, caveat, or question.
Hoffman et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: